Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
28
¥100 million (expected expense reductions)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedOperating profit+0.3%
基準 2,025Target2,031Hundreds of millions of yen
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
Net SalesNot disclosed → ¥60.6 billion (fiscal year ending March 2031)
Only the target level is shown because the current level for comparison was not provided.What happened to the previous plan¥15 billion (consolidated operating profit target under the Medium-Term Management Plan 2025) → -¥4.688 billion (consolidated operating loss for the fiscal year ending March 2026)+0.0%Calculated from the two disclosed figures
Key initiatives
01Discontinuation of the in-house clinical development project for gene therapy
02Withdrawal from GMP cell-processing contract services and prioritization of target modalities
03Clarification of management responsibility and streamlining of the management structure
04Workforce optimization
05In the reagents and instruments business, the company will expand earnings while limiting increases in allocated resources, in response to declining profitability of research catalog products amid the downturn in the global life sciences research market.
06In the CDMO business, the company will pursue thorough expense reductions, including through these structural reforms.
07In the gene medicine business, the company will continue to develop and manufacture for B2B customers, and focus on expanding sales of ancillary materials (AM products), including Retronectin® and enzymes for manufacturing mRNA vaccines, as well as media products. These are products used in the manufacture of biopharmaceuticals in the regenerative medicine, cell therapy and gene therapy fields, which are expected to achieve further growth.
08To achieve medium- to long-term growth, the company will expand its business beyond its traditional healthcare and medical fields into areas including the environment, industrial and energy applications, marine applications, and food and plants, using biotechnology, and will build a portfolio of technologies, products and services.
Non-financial targetsIndicator Number of voluntary retirements solicited / Target value Approximately 120 people / Timing 15 June–17 July 2026, Indicator Number of Directors / Target value Reduced from 9 to 3 / Timing Expected to be formally decided by resolution at the 24th Annual General Meeting of Shareholders
Risks identified by the company
Economic conditions, particularly consumer trends
Changes in Exchange Rates
Changes in laws and administrative systems
Pressure from competitors’ pricing and product strategies
Declining sales capabilities for our existing and new products
Production interruptions
Infringement of our intellectual property rights
Rapid technological innovation
An unfavorable judgment in significant litigation
Other factors affecting business performance, which are not limited to the above
Reason for revision or withdrawal
The consolidated operating loss for the fiscal year ending March 2026 was ¥4.688 billion, reflecting the continuing downturn in the global life sciences research market, substantial cuts in research grants in the United States, intensifying competition with competitors in China, the declining trend in development projects by major pharmaceutical companies in Japan's regenerative medicine, cell therapy and gene therapy fields, and a decline in CDMO contract projects due to changes in customers' development strategies, among other factors.
| Item | Details |
|---|---|
| Plan name | These structural reforms |
| Plan period | Start year: Not disclosed; final year: the fiscal year ending March 2031 (expense-reduction benefits will be realized over the two fiscal years from the fiscal year ending March 2027 through the fiscal year ending March 2028) |
| Progress against the plan | Formulated |
| Sales Target | Not disclosed → ¥60.6 billion (fiscal year ending March 2031) |
| Operating profit target | ¥15 billion (Medium-Term Management Plan 2025, FY2025) → ¥4.6 billion (fiscal year ending March 2031)（Approximately -69.3% (simple calculation)） |
| Non-financial targets | Indicator Number of voluntary retirements solicited / Target value Approximately 120 people / Timing 15 June–17 July 2026, Indicator Number of Directors / Target value Reduced from 9 to 3 / Timing Expected to be formally decided by resolution at the 24th Annual General Meeting of Shareholders |
| Key initiatives | Discontinuation of the in-house clinical development project for gene therapy, Withdrawal from GMP cell-processing contract services and prioritization of target modalities, Clarification of management responsibility and streamlining of the management structure, Workforce optimization, In the reagents and instruments business, the company will expand earnings while limiting increases in allocated resources, in response to declining profitability of research catalog products amid the downturn in the global life sciences research market., In the CDMO business, the company will pursue thorough expense reductions, including through these structural reforms., In the gene medicine business, the company will continue to develop and manufacture for B2B customers, and focus on expanding sales of ancillary materials (AM products), including Retronectin® and enzymes for manufacturing mRNA vaccines, as well as media products. These are products used in the manufacture of biopharmaceuticals in the regenerative medicine, cell therapy and gene therapy fields, which are expected to achieve further growth., To achieve medium- to long-term growth, the company will expand its business beyond its traditional healthcare and medical fields into areas including the environment, industrial and energy applications, marine applications, and food and plants, using biotechnology, and will build a portfolio of technologies, products and services. |
| Results under the previous plan | ¥15 billion (consolidated operating profit target under the Medium-Term Management Plan 2025) → -¥4.688 billion (consolidated operating loss for the fiscal year ending March 2026) |
| Reason for revision or withdrawal | The consolidated operating loss for the fiscal year ending March 2026 was ¥4.688 billion, reflecting the continuing downturn in the global life sciences research market, substantial cuts in research grants in the United States, intensifying competition with competitors in China, the declining trend in development projects by major pharmaceutical companies in Japan's regenerative medicine, cell therapy and gene therapy fields, and a decline in CDMO contract projects due to changes in customers' development strategies, among other factors. |
| Risks identified | Economic conditions, particularly consumer trends, Changes in Exchange Rates, Changes in laws and administrative systems, Pressure from competitors’ pricing and product strategies, Declining sales capabilities for our existing and new products, Production interruptions, Infringement of our intellectual property rights, Rapid technological innovation, An unfavorable judgment in significant litigation, Other factors affecting business performance, which are not limited to the above |
| Date of board resolution | 13 May 2026 |
| Publication date | 13 May 2026 |
Items this document does not state (13)
Operating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetPlan assumptionsSize of the Target Market
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Contract projects in the CDMO business have declined due to the downturn in the global life sciences research market, substantial cuts in research grants in the United States, intensifying competition with competitors in China, a declining trend in development projects by major pharmaceutical companies in Japan's regenerative medicine, cell therapy and gene therapy fields, and changes in customers' development strategies. In addition, with a view to becoming a wholly owned subsidiary of Takara Holdings, Inc., the company aims to transform its structure into one that generates sustainable earnings commensurate with its asset scale, while taking synergies into account.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.